Managing acute coronary syndrome: Evidence-based approaches

American Journal of Health-System Pharmacy

Volumn 64, Issue 11 SUPPL., 2007, Pages

  Spinler, Sarah A ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Angioplasty; Angiotensin converting enzyme inhibitors; Anticoagulants; Bivalirudin; Clopidogrel; Coronary disease; Dosage; Fibrinolytic agents; Geriatrics; Kidney failure; Mortality; Patient care; Platelet aggregation inhibitors; Protocols; Quality assurance

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FONDAPARINUX; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; MORPHINE SULFATE; RAMIPRIL; STREPTOKINASE; TENECTEPLASE; THROMBOPLASTIN; TIROFIBAN; TROPONIN; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; BLEEDING; BOLUS INJECTION; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTINUOUS INFUSION; CORONARY RISK; CORONARY STENT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EVIDENCE BASED MEDICINE; HEART CATHETERIZATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; INVASIVE PROCEDURE; LOADING DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 34249809430     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070109     Document Type: Conference Paper

References (33)

1. American Heart Association. Acute coronary syndrome. www.americanheart. org/presenter.jhtml?identifier=3010002 (accessed 2007 Jan 2).
2. CRUSADE National Quality Improvement Initiative. 2006 Crusade second quarter results. www.crusadeqi.com/Main/Ecab/Slides/CRUSADEResults2006Q2.ppt (accessed 2007 Jan 8).
3. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. 1998; 339:436-43.
4. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502.
5. Ferguson II, Califf RM, Antman EM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004; 292:45-54.
6. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002; 40:1366-74.
7. Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2006; 47:2130-9.
8. Mehta RH, Roe MT, Chen AY et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006; 166:2027-34.
9. Alexander KP, Chen AY, Roe MT et al. Antiplatelet and antithrombin dose variation in patients with non-ST-segment elevation acute coronary syndromes. Abstract presented at the American Heart Association's 6th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke (2005). Circulation. 2005; 111:e310-e359. Abstract 10.
10. Alexander KP, Chen AY, Newby LK et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation. 2006; 114:1380-7.
11. Stone GW, Bertrand M, Colombo A et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J. 2004; 148:764-75.
12. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355:2203-16.
13. Antman EM, Cohen M, Bernink PJ et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000; 284:835-42.
14. Lovenox package insert. Bridgewater, NJ: Aventis Pharmaceuticals Inc; November 2005.
15. Kaul S, Diamond GA. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. Prog Cardiovasc Dis. 2007;49:284-99.
16. Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa Inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002; 359:189-98.
17. Stone GW. Prospective, randomized comparison of routine upfront initiation versus selective use of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes: the ACUITY Timing Trial. clinicaltrialresults.org (accessed 2007 Feb 28).
18. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998; 338:1488-97.
19. McCullough PA, Gibson CM, Dibattiste PM et al. Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. J Interv Cardiol. 2004; 17:81-6.
20. Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001; 344:1888-94.
21. Lincoff AM, Kleiman NS, Kereiakes DJ et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaeous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004; 292:696-703.
22. Bovill EG, Terrin ML, Stump DC et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991; 115:256-65.
23. Chew DP, Bhatt DL, Lincoff AM et al. Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk. Heart. 2006; 92:945-50.
24. Yusuf S, Mehta SR, Chrolavicius S et al for the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354:1464-76.
25. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004; 44:671-719.
26. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352:1179-89.
27. Chen ZM, Jiang LX, Chen YP et al. Addition of dopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366:1607-21.
28. Gibson CM, Schomig A. Coronary and myocardial angiography: angiographic assessment of both epicardial and myocardial perfusion. Circulation. 2004; 109: 3096-105.
29. Sabatine MS, Cannon CP, Gibson CM et al. Effect of dopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005; 294:1224-32.
30. Plavix package insert. New York, NY: Sanofi-Synthelabo; August 2006.
31. Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006; 354:1477-88.
32. White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001; 358:1855-63.
33. Yusuf S, Mehta SR, Chrolavicius S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295:1519-30.